Drug target strategies in breast cancer treatment: recent developments

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer (BC) remains a leading cause of cancer death in women globally.
• Estrogen receptor (ER) targeted therapies are crucial but face challenges with primary and secondary resistance.
• Complex signaling pathways, including ER, EGFR, and mTOR, significantly influence BC endocrine therapy resistance.

Purpose of the Study:

• To review current targeted therapy approaches for breast cancer.
• To examine the roles of ER, EGFR, and mTOR signaling pathways in BC and their resistance mechanisms.
• To discuss the potential of PARP inhibitors for triple-negative breast cancer (TNBC).

Main Methods:

• Literature review of current research on ER, EGFR, and mTOR signaling in breast cancer.
• Analysis of resistance mechanisms in ER-targeted therapies.
• Evaluation of the current status of PARP inhibitors in BC chemotherapy.

Main Results:

• ER signaling is complex, involving multiple ER types and co-regulators, influencing therapeutic outcomes.
• EGFR and mTOR pathways crosstalk with ER signaling, contributing to endocrine therapy resistance.
• Triple-negative breast cancer (TNBC), often linked to BRCA mutations, currently lacks approved targeted therapies, but PARP inhibitors show promise.

Conclusions:

• Understanding ER, EGFR, and mTOR signaling is vital for developing novel BC targeted therapies.
• Targeting co-regulators and addressing pathway crosstalk are key strategies to overcome resistance.
• PARP inhibitors represent a promising therapeutic avenue for TNBC.